bioAffinity Technologies reports FY2023 revenue of $2.5M, up from $5K; CyPath Lung orders grow 350% in Q1 2024

bioAffinity Technologies, Inc.

2024-Q1 EPS reported -$0.20 revenue$2,406,391

FY2023 revenue $2.5M vs $5K in 2022; net loss $7.9M ($0.91/sh) vs $8.1M ($1.81/sh).
Q4 2023 revenue $2.2M vs nil prior year; net loss $2.4M vs $1.7M.
Cash and equivalents $2.8M at Dec 31, 2023.
CMS final payment determination for CyPath Lung for 2024; CyPath Lung orders up 350% in Q1 2024 vs Q4 2023.
Appointed Michael Dougherty as CFO; Dallas Coleman as National Director of Sales.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.

Period: the three and 12 months ended December 31, 2023
Revenue: $2.5 million
Net income: $7.9 million
EPS: $0.91 per share
Result: reported results

Exact text from the filing

expanding our market to fulfill the promise of early cancer detection and treatment.” Fourth Quarter Financial Results Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period. Revenue was derived from sales and services of the Company’s commercial laboratory, Precision Pathology Laboratory Services,

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.

Period: the three and 12 months ended December 31, 2023
Revenue: $2.5 million
Net income: $7.9 million
EPS: $0.91 per share
Result: reported results

Exact text from the filing

today reported financial results for the three and 12 months ended December 31, 2023. Fiscal Year 2023 and Recent Highlights ● Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath ® Lung,

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-012335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.